Skip to content

Replimune Group REPL Shares (Basic)

Shares (Basic) at other companies

Amgen logo
AmgenAMGN
540M+0.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
104M-2.5%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
15.6M+0.8%
Immunome logo
ImmunomeIMNM
113.1M+42.5%
CG Oncology logo
CG OncologyCGON
84.5M+10.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
304.3M+7.4%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$919.03M+28.6%
Enterprise value$873.59M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's shares (basic)?
Replimune Group (REPL) reported shares (basic) of 92.2M in Q4 2025.
How has Replimune Group's shares (basic) changed year-over-year?
Replimune Group's shares (basic) increased by 10.4% year-over-year, from 83.5M to 92.2M.
What is the long-term trend for Replimune Group's shares (basic)?
Over 3 years (2022 to 2025), Replimune Group's shares (basic) has grown at a 14.4% compound annual growth rate (CAGR), from 208.5M to 311.8M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.